A phase 1 study investigating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354, an Antibody-Drug conjugate targeting B7H3, alone and in combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in patients with advanced solid tumors

Description

This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid tumors. Study details include: * The study will be conducted in 2 phases: Phase 1a (Monotherapy Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion). * The visit frequency will be approximately every 21 days during study treatment. * The study duration is estimated to be approximately 5 years.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT06422520 Opens a new window